Pharsight

Ge Healthcare patents expiration

1. Myoview 30ml patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549999 GE HEALTHCARE Radiopharmaceutical composition
Mar, 2030

(5 years from now)

Drugs and Companies using TECHNETIUM TC-99M TETROFOSMIN KIT ingredient

Market Authorisation Date: 09 February, 1996

Treatment: NA

Dosage: INJECTABLE;INJECTION

More Information on Dosage

MYOVIEW 30ML family patents

Family Patents

2. Omniscan patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5560903 GE HEALTHCARE Method of enhancing paramagnetism in chelates for MRI
Oct, 2013

(10 years ago)

Drugs and Companies using GADODIAMIDE ingredient

Market Authorisation Date: 05 September, 2007

Treatment: NA

Dosage: INJECTABLE;INJECTION

More Information on Dosage

OMNISCAN family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Optison patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5529766 GE HEALTHCARE Contrast agents
Jun, 2013

(10 years ago)

US6723303 GE HEALTHCARE Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane
Apr, 2021

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-120) Aug 17, 2015

Drugs and Companies using ALBUMIN HUMAN ingredient

Market Authorisation Date: 31 December, 1997

Treatment: Ultrasound contrast agent

Dosage: INJECTABLE;INJECTION

More Information on Dosage

OPTISON family patents

Family Patents

4. Vizamyl patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7351401 GE HEALTHCARE Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition
Jan, 2023

(1 year, 4 months ago)

US8236282 GE HEALTHCARE Benzothiazole derivative compounds, compositions and uses
May, 2024

(23 days ago)

US7270800 GE HEALTHCARE Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
Sep, 2025

(1 year, 2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8691185 GE HEALTHCARE Benzothiazole derivative compounds, compositions and uses
Jan, 2023

(1 year, 4 months ago)

US8916131 GE HEALTHCARE Radiopharmaceutical composition
Sep, 2028

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 25, 2018

Drugs and Companies using FLUTEMETAMOL F-18 ingredient

NCE-1 date: 25 October, 2017

Market Authorisation Date: 25 October, 2013

Treatment: Diagnostic radioimaging

Dosage: INJECTABLE;INTRAVENOUS

More Information on Dosage

VIZAMYL family patents

Family Patents